By Keith Loria

Executive Overview

For decades, a diagnosis of feline infectious peritonitis (FIP) was regarded by veterinary professionals as a devastating, nearly uniformly fatal verdict. The landscape of veterinary medicine has shifted dramatically in recent years with the advent of effective antiviral therapies that can save lives. However, this therapeutic breakthrough has paradoxically magnified a persistent, frustrating challenge: the lack of a single, dependable antemortem test capable of definitively confirming or excluding FIP in every feline patient.

Because an accurate diagnosis can now lead directly to life-saving treatment, the stakes have never been higher. To address this critical diagnostic bottleneck, a team of researchers has evaluated a novel laboratory approach known as multiplex fluorescent immunocytochemistry (MF-ICC). Published in a recent diagnostic study, the assay aims to detect feline coronavirus antigen within macrophages—the primary target cells central to systemic FIP pathology—without requiring invasive surgical biopsies.

While the study revealed that MF-ICC demonstrated higher overall accuracy than several traditional diagnostic methods in the evaluated cohort, study authors emphasize a vital caveat: the test is not a silver bullet. Instead, diagnosing FIP continues to require an amalgamation of clinical signs, signalment, and a panel of complementary diagnostic tools. As veterinary medicine enters an era where FIP is actively treatable, refining diagnostic precision is no longer merely an academic exercise; it is a matter of life and death for countless cats worldwide.

Detailed Chronology: The Evolution of FIP Diagnostics and Treatment

To understand the significance of the latest research, it is necessary to examine how the clinical approach to FIP has evolved. Historically, veterinarians relied heavily on clinical intuition, biochemical abnormalities—such as an altered serum albumin-to-globulin ratio—and post-mortem examinations to diagnose the disease.

The Diagnostic Hurdle

Feline coronavirus (FCoV) is ubiquitous, particularly in multi-cat environments such as shelters, catteries, and multi-pet households. However, the vast majority of cats exposed to the enteric form of the virus never develop FIP. This high background prevalence complicates standard diagnostic testing.

• Serology detects an antibody response to the coronavirus, but it cannot differentiate between harmless exposure and systemic FIP.
• Reverse transcription-polymerase chain reaction (RT-PCR) looks for viral RNA, but it can yield false negatives or positives depending on viral shedding and sample site.
• Histopathology paired with immunohistochemistry (IHC) has long served as the gold standard for definitive diagnosis, but obtaining the necessary tissue samples typically requires an invasive surgical procedure—a risk that unstable, critically ill patients cannot safely endure.

The diagnostic challenge is most acute in the noneffusive (dry) form of FIP, where fluid accumulation is absent, and clinical signs can mimic a wide array of other chronic inflammatory or neoplastic conditions.

The Arrival of Antivirals and Raising the Stakes

The introduction of targeted antiviral medications fundamentally altered the prognosis for FIP patients. What was once an immediate prompt for euthanasia discussions became a treatable condition. Yet, this progress introduced new clinical dilemmas.

• Uncertainty delays therapy: When time is measured in days rather than weeks for a crashing patient, diagnostic ambiguity can cost a life.
• Empirical overtreatment: Without a firm diagnosis, some cats endure weeks of expensive antiviral therapy for diseases they do not possess, while their actual, underlying pathologies go untreated—a clear failure of antimicrobial and antiviral stewardship.

The Innovation of MF-ICC

Recognizing these barriers, a collaborative research team set out to evaluate multiplex fluorescent immunocytochemistry (MF-ICC) as a practical, minimally invasive alternative. Led by Samantha J.M. Evans, DVM, PhD, DACVP, DACVM, associate professor of clinical pathology at Colorado State University (CSU), the team investigated whether the assay could reliably identify the virus inside the specific cells driving the disease.

MF-ICC leverages fluorescent antibodies to target two key markers simultaneously: the feline coronavirus antigen and vimentin, a cellular marker that identifies macrophages. By superimposing images captured at different wavelengths, pathologists can determine if both markers are present within the exact same cell. This dual-positive identification provides much stronger evidence of systemic FIP than simply detecting free viral RNA or general antibodies.

Supporting Context & Metrics: Inside the CSU Diagnostic Study

The clinical trial conducted by Dr. Evans and her colleagues evaluated 84 feline patients: 58 confirmed cases of FIP and 26 control cases involving other systemic diseases. The researchers compared the performance of MF-ICC against three established diagnostic modalities:

1. RT-PCR assays
2. Serology testing
3. Serum albumin-to-globulin (A:G) ratios

Final case determinations for the study cohort were established through a rigorous combination of necropsy with histopathology and immunohistochemistry, documented response to antiviral treatment, and comprehensive clinical follow-up.

Quantitative Performance Metrics

Using a diagnostic threshold of at least one cell staining positive for both the viral antigen and the vimentin marker, MF-ICC demonstrated the following statistical performance within the cohort:

• Sensitivity: 77 percent
• Specificity: 81 percent
• Positive Predictive Value (PPV): 92 percent
• Negative Predictive Value (NPV): 53 percent
• Overall Accuracy: 78 percent

For comparison within the same study cohort, the overall diagnostic accuracy stood at 76 percent for the serum albumin-to-globulin ratio, 75 percent for serology, and 69 percent for RT-PCR.

Surprising Findings and Complementary Strengths

One of the most striking takeaways from the research was the minimal tissue threshold required for a positive indication. Dr. Evans noted her surprise that literally a single virus-infected cell was sufficient to discriminate between FIP and non-FIP disease cases.

Furthermore, the data showed that the various testing modalities did not always capture the exact same patients. According to Dr. Evans, MF-ICC successfully flagged FIP cases that RT-PCR missed, while PCR simultaneously identified cases that MF-ICC failed to detect. This non-overlapping performance underscores the value of a multi-test diagnostic panel rather than reliance on any single assay.

However, researchers stress that a negative MF-ICC result cannot reliably rule out FIP. Disease distribution, anatomical phenotype, and sample selection play major roles. For instance, cats presenting with neurologic or ocular FIP forms may harbor virus concentrations sequestered in sites that are exceedingly difficult to sample safely via routine fluid collection or fine-needle aspiration.

Official Statements and Expert Perspectives

The collaborative nature of the study brought together leading veterinary pathologists and internal medicine clinicians, all of whom emphasize the nuanced role of diagnostics in modern veterinary practice.

"FIP is extremely diagnostically challenging, primarily in the noneffusive form. It’s much more important now to get a diagnosis, because we actually have treatment available… It is not a panacea. We don’t have a silver bullet. It’s really an amalgamation of clinical signs and diagnostic tests that all come together to build a case for FIP, rather than a single test that we’re relying on."
— Samantha J.M. Evans, DVM, PhD, DACVP, DACVM, Associate Professor of Clinical Pathology, Colorado State University

Dr. Benjamin Curtis, DVM, DACVP, a clinical assistant professor at the University of Michigan’s Unit for Laboratory Animal Medicine Pathology Core and co-author of the study, highlights the procedural advantages of the technique for frontline veterinarians.

"It’s minimally invasive. Pulling fluid out of the belly or doing a needle aspirate is much less invasive than needing to do a tissue biopsy. But then it brings in the gold-standard concept of immunohistochemistry, in that we can confirm there is viral antigen inside the cells that matches the presentation of FIP… Having something with a rapid turnaround is going to be life and death for a lot of cats."
— Benjamin Curtis, DVM, DACVP, Study Co-Author

Addressing the clinical hazards of diagnostic delays and empirical guesswork, Dr. Petra Černá, PhD, DACVIM (SAIM), Dipl. ECVIM-CA, DABVP (Feline), MANZCVS, assistant professor of small animal internal medicine at the University of Georgia and a study co-author, stresses the importance of precision stewardship.

"It is very important to have access to fast and accurate diagnostic tests so we can confidently treat these cats. Very often, I see cases that have been treated for several weeks with antiviral therapy, and they do not have FIP. That is not good antiviral stewardship, but we are also missing the actual diagnosis and are not able to help these patients."
— Petra Černá, PhD, DACVIM, Study Co-Author

Future Outlook: Building a Comprehensive Diagnostic Ecosystem

Translating MF-ICC from a research setting into a widely accessible clinical service represents the next major milestone. The assay is not currently designed as an in-clinic "snap" test; it demands specialized laboratory equipment to concentrate cellular material onto slides, precise fluorescent reagents, and board-certified veterinary pathologist expertise to interpret the complex staining patterns.

Colorado State University’s Veterinary Diagnostic Laboratory plans to operationalize the assay, offering it as part of an integrated FIP diagnostic service package. Rather than positioning MF-ICC as a standalone replacement for existing tests, CSU intends to bundle MF-ICC, RT-PCR, albumin-to-globulin ratios, and patient clinical metrics into a unified submission panel.

Expanding Horizons and Unanswered Questions

As more feline patients survive FIP due to accessible antivirals, veterinary science faces entirely new clinical horizons:

• Machine Learning Integration: Researchers are actively developing machine-learning tools driven by routine complete blood count (CBC) and serum biochemistry findings to assist practitioners in calculating risk indices.
• Comorbidities and Relapses: Clinicians are encountering complex cases involving severe systemic inflammation, suspected viral sepsis, immune-mediated hemolytic anemia, myocarditis, and concurrent infections that complicate standard antiviral protocols. Managing these overlapping conditions remains a critical area for ongoing clinical research.
• Long-Term Post-Recovery Health: With historical mortality rates near 100 percent, long-term health outcomes for cured cats were previously unstudied. Emerging reports of post-recovery gastrointestinal complications and large-cell lymphoma highlight the necessity for longitudinal veterinary studies.

Ultimately, the refinement of assays like MF-ICC moves the veterinary community closer to the ultimate goal: a rapid, minimally invasive diagnostic system that provides definitive answers within hours, sparing feline patients from guesswork and empowering clinicians to initiate life-saving therapy with absolute confidence.

Keith Loria is a D.C.-based, award-winning journalist who has spent nearly two decades writing for major publications on veterinary medicine, healthcare, and technology. He began his career with the Associated Press.